Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-based randomized phase 2 trial in chemotherapy-refractory KRAS wild-type metastatic colorectal cancer
ACTRN12611001142921Phase 2Terminated
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Mar 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cetuximab, erlotinib, doxycycline and hydrocortisone in colorectal cancer (CRC) and cutaneous reaction (5 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Tumor response rate. Started Mar 2012; status: terminated.
02
Drugs
cetuximaberlotinibdoxycyclinehydrocortisone
03
Conditions
colorectal cancer (CRC)cutaneous reaction
Beyond the preview
Go deeper on ACTRN12611001142921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001142921.